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The patient was an 85-year-old female with severe symptomatic aortic stenosis and symptoms of chronic heart failure 
(class III according to the New York Heart Association functional classification). The presence of several comorbidities in-
cluding arterial hypertension, severe chronic obstructive pulmonary disease requiring long-term use of bronchodilators and 
steroids, chronic kidney disease, atrial fibrillation and diabetes contributed to the logistic Euroscore I of 16%. The subject 
had undergone percutaneous coronary intervention (PCI) in left ascending artery (LAD) with drug eluting stent implantation 
one month earlier. An echocardiographic assessment revealed a left ventricular ejection fraction of 68%, tricuspid, calcified 
aortic valve with valvular gradient 70/44 mm Hg and aortic valve area of 0.8 cm2. In transoesophageal echocardiogram, 
the aortic annulus diameter was 24 mm. Coronary angiography did not show any significant atherosclerosis in coronary 
vessels, and a good result of PCI LAD. Computed tomography (CT)-angiography of iliac and lower limb arteries revealed 
diameters of right and left common femoral artery of 8 mm and 9 mm, respectively. The subject was discussed at a Heart 
Team meeting and scheduled for transcatheter aortic-valve implantation (TAVI) with a recommendation for femoral ac-
cess and the use of a 26 mm Edwards Sapien 3 prosthesis (Edwards Lifesciences, Irvine, CA, USA). TAVI procedure was 
performed under general anaesthesia and under transoesophageal echocardiography control. A temporary pacemaker 
for rapid pacing was inserted via right subclavian vein access. A diagnostic 6 French pigtail catheter was introduced to 
the ascending aorta through the right ra-
dial artery for intraprocedural imaging pur-
poses. Balloon aortic valvuloplasty was per-
formed using a 20 × 40 mm balloon under 
pacing at 180 bpm. Afterwards, a successful 
implantation of a 26 mm Edwards-Sapien 
3 valve (14 F delivery system) under pacing 
at 180 bpm was performed (Figs. 1, 2). The 
duration of the procedure was 100 min with 
0.7 mGy of radiation. The post-procedural 
transthoracic echocardiogram showed 
a gradient of 16/7 mm Hg with no aortic 
regurgitation and no paravalvular leaks 
(Fig. 3). At 45 days follow-up, the patient 
remains asymptomatic with aortic gradient 
of 19/8 mm Hg and no aortic regurgitation. 
Edwards Sapien 3 prosthesis is a novel de-
vice for TAVI procedures to improve results 
of valve implantation mainly by reducing 
the risk of paravalvular leaks due to a new 
design of valve prosthesis, inner and outer 
‘skirt’. Moreover, ultra-low delivery profile 
with 14 F could provide lower risk of vas-
cular complications. 
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Figure 3. No aortic regurgitation and paravalvular leaks after TAVI
Figure 1. Edwards Sapien 3 after 
TAVI in fluoroscopy
Figure 2. Edwards Sapien 3 valve with 
outer and inner skirt
